Inflammatory Bowel Disease

A short form of the esophageal hypervigilance scale similarly measured symptom severity and quality of life compared with the longer test, according to a recent study. It was the top story in gastroenterology last week.

Risk of inflammatory bowel disease was generally low among individuals with acne vulgaris treated with isotretinoin, according to a study.

When a disease has no clear etiology and no cure — as is the case with Takayasu arteritis — any advance feels like a big advance.

Anticoagulation use or antiplatelet agents were not risk factors for gastrointestinal bleeding in hospitalized COVID-19 patients, according to a study published in Journal of Internal Medicine.

First-line Remicade therapy was superior to conventional treatment in achieving short-term remission in children with Crohn’s disease, according to study results.

In this exclusive video, Anita Afzali, MD, director of the inflammatory bowel disease center at The Ohio State University, discusses the impact of emerging therapies in IBD.

In this exclusive video, Freddy Caldera, DO, MS, assistant professor of medicine in the division of gastroenterology and hepatology at the University of Wisconsin School of Medicine and Public Health, spoke about the two recent COVID-19 vaccines that have been authorized for emergency use.

Polygenic risk scores compiled using data from a multi-ethnic biobank helped improve predictions for inflammatory bowel disease, according to study results.

Healio Gastroenterology looks back at the Peer Tested content from online and print as it fared throughout the year and what made us stand out in 2020.

Over the last decade-plus, the introduction of several key therapies has shaped the management of inflammatory bowel disease.